To report the authors' early experience with radio-frequency (RF) abla tion of renal cell carcinoma.
RESULTS:
All five exophytic tumors were free of enhancement. One of three central tumors was free of enhancement. One tumor had both central and exophytic components and was free of enhancement. Three tumors were 3 cm or smaller and free of enhancement. Of the six tumors larger than 3 cm, four were free of enhancement.
CONCLUSION:
Percutaneous RF ablation is a promising treatment for select pa tients with renal cell carcinoma. The ultimate role of this modality will continue to evolve and warrants further study.
New cases of renal cell carcinoma occur in up to 30,000 people in the United States annually (1) . The conventional treatment for renal cell carcinoma has been nephrectomy. However, recent advances in surgical techniques have led to the use of partial nephrec tomy or laparoscopic nephrectomy in select patients (2) (3) (4) (5) . For many patients, open complete nephrectomy, partial nephrectomy, or laparoscopic nephrectomy remains the choice for treatment of renal cell carcinoma. However, for some patients, a less invasive treatment would be desirable. For example, given the slow-growing nature of renal cell carcinoma, patients who are poor surgical candidates or have limited life expectancy could benefit from an effective minimally invasive procedure. In addition, a nonsurgical option could also benefit patients with an underlying predisposition to multiple renal cell carci nomas, such as patients with von Hippel-Lindau disease. With advances in computed tomography (CT) and ultrasonography (US) and the increasing use of these modalities, renal cell carcinomas are being detected incidentally at an increasing rate (6, 7) . Moreover, the incidence of renal cell carcinoma may be increasing (8).
The application of thermal energy by means of radio frequency (RF) to destroy benign or malignant tumors has proved to be successful for osteoid osteomas (9) and small primary and metastatic liver lesions (10 -12) in humans. The results of recent animal studies (13, 14) have demonstrated the feasibility of RF ablation in the kidney. In addition, Zlotta et al (15) reported on a series of renal tumors in humans that were treated with RF ablation and then resected. McGovern et al (16) reported a case of in vivo RF ablation in a patient with renal cell carcinoma (16) but without follow-up. To the best of our knowledge, however, to date, no short-or long-term results from nonexcised, percutane ously treated tumors are available. The purpose of our study was to report our early experience with RF ablation of renal cell carcinoma, with imaging follow-up. Illustration of the various renal cell carcinoma locations expected to influence the results of RF ablation on the basis of tumor contact with perirenal fat, renal parenchyma, and large central vessels. A, Exophytic tumors (shaded) with progressively more contact with renal parenchyma and less contact with perirenal fat are shown. At the extreme (far right) is a tumor completely within the parenchyma with no component surrounded by perirenal fat. This tumor would be considered an intraparenchymal renal cell carcinoma. For purposes of assessing RF ablation results, the tumors were classified as exophytic when 25% or more of the tumor diameter was in contact with perirenal fat. B, Central tumor, which by definition extends into the renal sinus but not beyond the renal capsule. C, Mixed tumor with components in both the renal sinus fat and the perinephric fat.
MATERIALS AND METHODS

Indications for Treatment and Patient Characteristics
At the time this article was written, we had begun a prospective study 21 months previously to treat renal cell car cinomas in selected patients with RF ab lation. In this preliminary experience, the indications for RF ablation were life expectancy shorter than 10 years, with substantial coexistent morbidity (eg, other malignancy, coronary arterial dis ease, peripheral vascular disease, diabe tes) and/or a solitary kidney. Patients were excluded when they had metastatic disease or were deemed to be candidates for nephrectomy at urologic consulta tion; an exception was one patient who refused to undergo nephrectomy. On the basis of these criteria, eight patients were deemed to be eligible and were treated with RF ablation. All but one patient had a baseline creatinine level lower than 2.0 mg/dL (152.5 �mol/L) (range, 0.9 -2.3 mg/dL [68.6 -175.4 �mol/L]). The study was undertaken with the approval of our institutional human studies committee, and written informed consent was ob tained from all patients.
Tumor Characteristics
A total of nine tumors were treated in eight patients. Five tumors were on the left, and four were on the right. All tu mors were imaged before RF ablation with contrast material-enhanced CT (with ioxilan 62% [Oxilan-300], 300 mg of iodine per milliliter; Cook, Blooming ton, Ind) (n � 8) or magnetic resonance (MR) imaging (with gadopentetate dime glumine [Magnevist] ; Berlex Laborato ries, Wayne, NJ) (n � 1). Diagnosis of a tumor as renal cell carcinoma was based on the following criteria: needle biopsy findings positive for renal cell carcinoma (n � 7), enlarged enhancing renal mass at CT with two nondiagnostic biopsies (n � 1), and an enlarged enhancing mass at MR imaging (n � 1). Although biopsy proof was not available for two tumors, their solid nature, enhancement, and en largement at serial imaging supported their inclusion in this study. Preablation contrast-enhanced and nonenhanced CT scans were obtained in all patients who had a baseline creatinine level of 2 mg/dL (152.5 �mol/L) or lower. Otherwise, con trast-enhanced and nonenhanced MR imaging was performed.
Tumor size ranged from 1.2 to 5.0 cm in largest diameter, with a mean diame ter (� SD) of 3.3 cm � 1.1. The enhance ment of all lesions was greater than 15 HU. The tumor assessed with MR imag ing was enhancing on the basis of quali tative evaluation of the pre-and postcon trast images. Six tumors were larger than 3 cm, and three were 3 cm or smaller. Five tumors were classified as exophytic, which we defined as at least 25% of the tumor extending beyond the renal con tour with no tumor extending into or up to the renal sinus (Fig 1) . Three tumors were classified as central, which we de fined as tumor limited to the confines of the renal contour and extending into the sinus. One tumor was classified as mixed because it showed both extension into the renal sinus and extension beyond the renal contour.
Preprocedural Assessment
All patients were examined by urology and interventional radiology services per sonnel before the ablation procedure. This evaluation included a 1-hour preprocedural visit to the interventional ra diology service. Preprocedural coagula tion studies-that is, baseline hemato crit, platelet count, prothrombin time, and partial thromboplastin time testswere performed. In addition, during the same initial visit, one of the interven tional radiologists (D.A.G. or P.R.M.) per formed limited renal US to assess the suit ability for US-guided electrode place ment. This step enabled us to schedule those patients whose tumors were not seen well at US to undergo their ablation procedures with CT guidance. By using this strategy, six tumors were deemed to be appropriate for US-guided RF ablation and three were deemed to be appropriate for CT-guided RF ablation.
RF Ablation Procedure
All RF ablation treatments were sched uled as outpatient procedures to be per formed early in the day to allow appro priate postprocedural monitoring of pa tients for possible complications that might necessitate hospital admission or additional treatment before discharge. All procedures were performed with in travenous sedation that consisted of mi dazolam (2-5 mg), fentanyl (100 -300 mg), and droperidol (0.625 mg), as needed. Intravenous sedation was in duced by an interventional radiology nurse according to institutional guide lines. Monitoring of vital signs, cardiac rhythm, and pulse oximetry was per formed. In addition to intravenous anal gesia, local analgesia with 1% lidocaine was administered.
RF ablation was performed with an RF generator (Cosman Coagulator CC-1; Ra dionics, Burlington, Mass) by using a sin gle (with one 2.0 -3.0-cm tip) or cluster (with three 2.5-cm tips) cooled-tip elec trode. The type (single or cluster) of elec trode and length of the exposed tip were chosen by the operator on the basis of tumor size and location. In general, tu mors 3 cm or smaller were treated with a single electrode. Tumors larger than 3 cm were treated with a single electrode when they were exophytic, with the exception of one area of residual disease, which was treated with a cluster electrode. Early in our experience, we treated one central tumor with a single electrode. However, the limited effect of the single electrode on a large central tumor led us to treat subsequent central tumors with a cluster electrode, which has a cluster of three tips. Cooling of the electrode tip was ac complished by using perfusion of iced saline solution or water (17). Once the electrodes were deemed to be in the ap propriate location for treatment, a 12 minute treatment session was performed by increasing the current to 1,500 -1,800 mA for 1 minute and monitoring the im pedance for any rapid increase over base line.
Pulsing of current (ie, temporarily re ducing the RF current for 10 -15 seconds) was performed, as necessary, when rapid increases in impedance were measured. Initially, pulsing was performed manu ally by the operator. During the course of the study, however, a computer chip that allowed pulsing to be automated became available. Pulsing is performed in re sponse to rapid increases in impedance, which are usually related to local tissue charring, which limits further heat diffu sion. Reducing the current limits the charring. The current is then increased slowly to a therapeutic level. This RF ab lation technique has been previously op timized in liver tumors to maximize treated volumes (18).
Once the 12-minute treatment was complete, the electrode was placed in a different location in the tumor, if needed, to treat the entire volume of the tumor. A treatment was defined as one 12-minute RF application. A session was defined as one visit to the radiology de partment, where one or more RF applica tions were performed. During a visit, the need for additional treatments was deter mined on the basis of tumor size and shape. Small tumors were treated with a single placement of the electrode cen trally within the tumor. Larger and/or complex-shaped tumors were treated by placing the electrodes eccentrically in the tumor to create overlapping volumes of ablated tumor. Second and third treat ments were performed, as needed, in the same manner. Because neither the US nor nonenhanced CT findings during RF ab lation of liver or other tumors reliably predict the treatment results, the imag ing findings observed during the proce dure were not used to guide therapy (19). However, for tumors treated with US guidance, the changes in lesion echotex ture during and after RF ablation were noted.
Postprocedural Monitoring
Physiologic monitoring was continued during the recovery period in the inter ventional radiology recovery unit, where patient activity was allowed to increase as tolerated after 2 hours of bed rest. All patients were monitored for pain, hypo tension, and hematuria after the proce dure. Microscopic hematuria was as sessed with reagent strips (Multistix; Bayer Diagnostics, Elkhart, Ind). Patients were discharged to the care of another adult 3-4 hours after the procedure when the following criteria were met: stable vi tal signs, no residual gross hematuria in the most recent urine specimen, no sub stantial flank pain at rest, and toleration of oral intake of liquids and solids. Oth erwise, the patients were admitted to the hospital.
Postprocedural CT imaging on the day of the procedure was not routinely per formed; it was performed only when the interventional radiologist was concerned about a complication such as hematoma. The clinical parameters that determined the need for immediate postprocedural CT were postprocedural hypotension, higher than expected degree of pain or tenderness, and/or gross hematuria.
Postprocedural Imaging Assessment
All patients were followed up with con trast-enhanced imaging. The imaging study of choice was focused renal CT, with 5-mm sections obtained with and without intravenous contrast material. The patients were monitored by using CT (n � 7), with the exception of one pa tient, in whom impaired renal function (ie, creatinine level �2 mg/dL [152.5 �mol/L]) precluded the administration of iodinated contrast material. In this pa tient, gadolinium-enhanced MR imaging was used to monitor treatment. Postabla tion imaging was performed at 1, 3, and 6 months. Two authors (D.A.G., P.R.M.) evaluated the postprocedural images for tumor size, tumor enhancement, and ev idence of metastatic disease by means of consensus. Subsequent imaging was per formed at 6-month intervals. Patients with residual enhancing tumor were re treated with RF ablation targeting the area that showed persistent enhance ment. Any lesion that was enhancing more than 10 HU after contrast material administration was considered to be un treated tumor. At MR imaging, any qual itative increase in the signal intensity of the tumor after contrast material admin istration was considered to be untreated tumor. Our bases for this protocol were data extrapolated from the radiologicpathologic correlation in liver tumors performed by Goldberg et al (20) . Repeat biopsy was not performed.
RESULTS
Nine tumors were treated in eight pa tients. These patients required a total of 24 treatments during 14 visits. Four pa tients (five tumors) were treated in one ablation session, and four required more than one session on the basis of imaging evidence of residual tumor. Three of the latter four patients required two visits each. One of these four patients required four visits. These data are summarized in the Table. In eight visits, RF ablation was performed with US guidance, and in six, it was performed with CT guidance. Twelve of 14 patient visits were com pleted on an outpatient basis. Two visits resulted in hospital admission.
Patient Follow-up
Complete results, by patient and tumor characteristics, are given in the Table. Sixmonth follow-up imaging data were avail able in seven of the eight patients. The length of follow-up ranged from 3 to 21 months (mean, 10.3 months). Seven of nine tumors were completely treated. The smaller and exophytic tumors necessitated fewer treatments than did the larger cen tral tumors.
Small Exophytic Tumors
All three small (�3-cm) exophytic tu mors were completely free of enhance ment at 6 months or longer (Fig 2) . These lesions necessitated only one treatment, which was performed with a single inter nally cooled RF electrode and US guid ance. Two lesions were treated with a 2-cm active electrode tip, and one was treated with a 3-cm active electrode tip. One of these patients died of leukemia diagnosed 6 months after RF ablation, and two were alive and healthy 13 and 21 months after ablation.
Large Exophytic Tumors
Two large (�3-cm) exophytic tumors were treated. The first was nearly com pletely exophytic (�10% of diameter within renal parenchyma) and measured 3.5 cm in maximum axial diameter. This tumor was ablated in a single treatment with a 3-cm exposed-tip electrode and was free of enhancement at 6 months. We treated one exophytic tumor that measured 3.4 cm in maximum axial di mension and extended 3-4 cm in the cephalocaudal dimension. This tumor was surrounded by parenchyma over ap proximately 40% of its axial diameter. Two treatments with a single electrode with a 3-cm active tip were performed during the first visit. The electrode was positioned in the caudal and cephalic as pects of the tumor. CT at 1 month de picted no enhancement in the caudal as pect of the lesion. However, the posterior half of the cephalic aspect of the tumor continued to demonstrate residual en hancement. The enhancing region was targeted with US guidance and ablated with one additional treatment with a cluster electrode. Imaging at 6 months after the second visit demonstrated no evidence of residual disease (Fig 3) .
Large Central Tumors
We treated three large (�3 cm) central tumors. Two were in patients with soli tary kidneys following contralateral ne phrectomy. These two tumors were deemed not to be amenable to nephronsparing surgery. The other lesion was a recurrent tumor in a partial nephrectomy bed that manifested 2 years after the sur gery. The first of these large tumors mea sured 4.4 cm and extended from the up per pole to the middle of the renal sinus (Fig 4) . This tumor was initially targeted with a 3-cm single electrode, and two treatments were performed during the first visit. Imaging within 1 month dem onstrated a large focus (�50%) of residual enhancement. Treatment was then per formed with a cluster electrode. How ever, small peripheral regions of residual enhancement necessitated additional treatments. At the time this article was written, this patient had undergone eight treatments during four visits. At 1 year after starting treatment, approximately 80% of the tumor no longer showed en hancement. At the time this article was written, the patient had a small (�1 cm) crescent of residual lateral enhancement and no metastatic disease.
The second large central tumor was 3.4 cm in diameter and in a partial nephrec tomy bed. Its boundaries were not well demonstrated at US, and ablation was per formed with CT guidance. The tumor was treated once with a cluster electrode placed 668 � Radiology � December 2000
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In all patients except patient 8, the tumor enhancement measurements are attenuation values at CT, expressed in Hounsfield units. In patient 8, enhancement at contrast-enhanced MR imaging was * assessed qualitatively as any increase in signal intensity compared with that at nonenhanced MR imaging. † Patient 2 had two tumors treated on the right kidney during the same visit. This patient died of leukemia complicated by intracranial hemorrhage and respiratory failure 6 months following RF ablation. All other patients were alive at the time this article was written. ‡ Exophytic-central type tumor. beyond the renal parenchyma both into the central sinus fat and beyond the outer renal contour. This patient re quired two visits and four US-guided RF applications with a cluster electrode. Fol centrally. This patient was without tumor enhancement 9 months after treatment.
The third patient with a large central lesion had a 5-cm tumor that demon strated interval enlargement during 6 months. US-guided RF ablation was per formed in two treatments with a cluster electrode. Subsequent CT depicted en largement of the tumor to 7 cm and very little (�15%) treatment effect. The pa tient was re-treated in two additional treatments with CT guidance and a 2.5-cm cluster electrode. Imaging within 1 month after the second visit demon strated that the tumor size had decreased to 6 cm, and approximately 70% of the tumor was enhancing.
Mixed Tumors
We treated one mixed tumor, which was 4.1 cm in diameter with extension low-up MR imaging 1 month after the second visit depicted no residual en hancement and a decrease in tumor size.
Summary of Patient Results
All five exophytic tumors and all three tumors 3 cm or smaller were free of en hancement at 6 months or longer after ablation; only one of the three central tumors was free of enhancement. The two tumors with persistent enhancement were larger (4.4 and 5.0 cm) and necessi-tated repeat treatments: One patient re quired treatment during four separate visits, and the other required treatment during two visits. Approximately 80% of one of these tumors was treated. Less than 50% of the other tumor was treated, but RF ablation seemed to have stopped its enlargement. No patients developed metastatic disease during the study pe riod. In addition, renal function re mained stable in all patients, as evi denced by their creatinine levels. At the end of the study, all but one patient were alive and none had manifestations of re nal cell carcinoma.
Imaging
As described with RF ablation of liver lesions, the US findings during RF ablation of renal cell carcinoma were intense echoes spreading from the active electrode tip. In all cases, these echoes reversed 5-10 min utes following treatment, leaving the le sions of heterogeneous echotexture; there was no correlation between the US appear ance and the later findings at contrast-en hanced CT or MR imaging. Early in our experience, one patient underwent con trast-enhanced CT the day of the proce dure; this resulted in an underestimation of the residual disease seen at 1-month fol low-up. On the basis of this experience, we changed our practice and no longer obtain a routine CT or MR image on the same day of the procedure.
Five tumors (in four patients) showed no enhancement after one visit (Fig 2) . Imaging within 1 month after the proce dure demonstrated residual enhance ment in four tumors, which were all re treated (Figs 3, 4) . Two of these four patients had no residual enhancing tu mor at imaging after the second session. The seven tumors that no longer show enhancement showed a decrease in at least one axial dimension over time.
Complications
Two complications were noted during 14 visits. One patient experienced a 5-10 minute dystonic reaction to fentanyl. His extremities and chest wall became rigid, but he maintained spontaneous respira tion despite being unresponsive to com mands and painful stimuli. He recovered rapidly, and afterward we were able to complete the procedure. During the same visit, further therapy for a second tumor in this patient was without incident. Because he had no family at home, he was admit ted for overnight observation and dis charged in good condition the next morn ing.
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The patient with the largest central le sion and a solitary kidney experienced transient hypotension accompanied by flank tenderness within 1 hour after RF ablation. CT depicted a large paranephric space hematoma and blood within the renal pelvis. The patient was anuric from clot obstructing the collecting system and experienced a transient increased cre atinine level-from 1.7 (129.6 �mol/L) to 2.9 mg/dL (221.1 �mol/L). Treatment consisted of cystoscopic ureteral stent placement and blood transfusion. The patient was discharged 3 days later, and his creatinine level returned to baseline. He recovered completely and continued with RF ablation of residual tumor.
Although gross hematuria was seen only in the patient with the major hem orrhage, microscopic hematuria was com mon. The first urine specimen from five (62%) of the eight patients showed mi croscopic hematuria. In all cases, the mi croscopic hematuria resolved prior to dis charge.
DISCUSSION
Management options for renal cell carci noma continue to evolve, with the most recent developments being in the areas of nephron-sparing surgery and laparo scopic procedures (2) (3) (4) (5) . On the basis of a mean growth rate of 3-4 mm per year, follow-up imaging of small incidentally discovered renal cell carcinomas has been advocated in older patients to avoid nephrectomy or surgery (21, 22) . How ever, in select cases, a successful mini mally invasive percutaneous procedure could allay patient anxieties related to untreated tumor and prevent surgery in some cases. RF ablation of malignant tu mors has been a feasible option for pa tients with primary and metastatic liver lesions (10 -12) who were not amenable to surgery, and it probably will have a role in the management of select renal lesions. The results of early work in ani mals and tumors in humans that were treated with RF ablation intraopera tively and resected after ablation indi cate promising results with RF ablation of renal tumors (13) (14) (15) . In this study, we prospectively evaluated RF ablation in se lected cases of renal cell carcinoma to investigate the technique, procedural de tails, results, and complications of this procedure. Our follow-up imaging results indicated successful treatment.
Our early results with RF ablation of renal cell carcinoma are encouraging for lesions 3 cm or smaller and exophytic lesions, all of which were successfully treated, as proved by the imaging criteria. Treatment of large central lesions proved to be more challenging: More treatments and patient visits were required for these tumors compared with those for their small or exophytic counterparts.
A key limitation of RF ablation is the size of the lesion that can be successfully treated. Despite advances in electrode de sign that permit large volume coagula tion in ex vivo tissue, complete ablation of tumors larger than 3-4 cm has been challenging (10, 17, 23, 24) . One reason is that blood flow through and around tu mor has a cooling or "heat sink" effect by constantly replacing heated blood with cooler blood at body temperature. Thus, coagulation in in vivo liver, with its dual blood supply from the portal vein and hepatic artery, yields smaller ab lated tissue volumes than does coagulation in muscle (17, 24) . Renal parenchyma is highly vascular because kidneys are per fused by 20% of the circulating blood volume. Thus, central tumors surrounded by renal parenchyma, with its high blood flow and large central vessels, are ex pected to be more difficult to treat than exophytic tumors surrounded by perire nal fat, which is relatively avascular.
On the other hand, with exophytic le sions, the location may be beneficial. Fat has an insulating effect and thus in creases the temperatures that can be reached in the tumor. This is analogous to the so-called "oven effect," which has been described in hepatomas and results from the insulation provided by the hep atoma capsule and the cirrhotic liver (25) . These considerations led us to adopt the classification scheme shown in Figure  1 to allow assessment of RF treatment results on the basis of tumor location.
As was expected because of their small size and favorable location, all three of the small (�3-cm) exophytic lesions in our study were treated during one visit and with one treatment each. One of the large (�3-cm) exophytic tumors was treated with a single placement of a 3-cm single electrode. This tumor was 3.5 cm and nearly completely surrounded by fat. However, more aggressive treatmentthat is, with cluster electrodes and multi ple treatments-was required for the sec ond large exophytic tumor, which was treated completely but necessitated a sec ond visit.
Tumor enhancement was eradicated with a single treatment in one of three patients with a large central lesion. This tumor was a recurrent renal cell carci noma in a partial nephrectomy bed that was treated with a single treatment with a cluster probe. There probably was sub stantial scarring and fibrosis associated with this tumor, as indicated by the re sistance felt when the biopsy needle and RF electrodes were advanced. Surround ing fibrosis is expected to reduce thermal conduction and thus improve tumor treatment. The other two tumors of this type were larger and necessitated more aggressive treatment. Although complete treatment may have been elusive in the largest tumor, RF ablation probably played a palliative role in slowing tumor growth.
Treatment of mixed lesions is expected to yield intermediate results. In the cur rent study, our experience with these types of lesions was limited to a single tumor, with 3 months of follow-up and no residual enhancement after four treat ments.
We have found that the preprocedural visit is indispensable in planning the pro cedure and facilitating a timely start on the day of the procedure. Coagulation studies and the appropriate choice of im aging guidance are all addressed before the day of the procedure. In addition, the education and consent processes for ther apeutic procedures directed to tumor therapy can be time consuming. Patients and families need many questions an swered and their fears addressed. The op portunity to return home and discuss the procedure with family and consider all the options rather than rushing into the procedure served our patients well. At tention to these details during the preprocedural visit reduced the procedure time.
The two complications encountered in our series were managed without longterm adverse effects on the patients. The reaction to fentanyl was not directly re lated to the procedure. Even major com plications, such as the hemorrhage re quiring transfusion and ureteral stent placement, can be managed without an operative procedure in most cases. How ever, the operator and patient should be prepared for hospital admission if neces sary. Furthermore, patients with solitary kidneys should be informed of the possi bility of renal injury leading to loss of function and the need for dialysis.
To our knowledge, little is known about the imaging appearance of renal cell carcinoma after RF ablation. As with those during RF ablation of liver lesions, findings during US-guided RF ablation do not accurately reflect the ultimate treat ment result (19). During RF ablation, the tumor surrounding the electrodes be comes intensely echogenic, but the tissue volume treated does not correlate with the distribution of these echoes (26) . These echoes usually resolve within min utes after RF ablation and are thought to be secondary to microbubbles generated during tissue ablation. Immediate con trast-enhanced CT has resulted in an un derestimation of residual disease in many of our patients who have undergone RF ablation of liver lesions. On the basis of these experiences, we consider immedi ate contrast-enhanced CT to be unreli able for assessing the adequacy of abla tion.
We assessed our follow-up posttreat ment images with the same criteria that are used for primary and secondary liver tumors treated with RF ablation. In liver lesions, residual or new areas of enhance ment have been shown to correlate with active tumor at pathologic analysis (19, 20) . We assessed the treated renal cell carcino mas for lesion size and enhancement. Re sidual areas of enhancement were consid ered to represent active disease and thus re-treated. On the basis of our preliminary experience, this approach appears to be justified. However, our mean follow-up time of 10.3 months was short with respect to the expected growth rate of small renal cell carcinomas (21, 22) . Long-term results are needed to assess the possible small re gions of residual tumor that are below the resolution of our imaging capabilities.
The appropriate role of RF ablation of small tumors probably will evolve. Tu mors smaller than 3 cm are known to have a slow growth rate, and some inves tigators (18,19) have advocated serial im aging of these tumors in older or debili tated patients because these individuals may never have substantial clinical prob lems related to these small renal cell car cinomas. Given that, according to exten sive experience with liver tumors and the results of our more limited series of renal tumors, the general success rate of RF ab lation decreases with increasing tumor size, serial imaging may be appropriate until a lesion reaches 2.5-3.0 cm in max imum dimension or shows rapid growth not related to hemorrhage. Percutaneous RF ablation would then be a minimally invasive alternative to surgery.
In conclusion, percutaneous RF abla tion is a promising minimally invasive therapeutic modality with an evolving role in the management of select cases of renal cell carcinoma. Treatment is more likely to be successful with smaller (�3 cm) and exophytic tumors. Although longer-term patient follow-up is needed, our preliminary results are encouraging.
